Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireFebruary 19, 2026BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25th through Thursday, February 26th.
Fireside Chat Details
Date: Wednesday, February 25, 2026
Time: 1:20 p.m. ET
To access a replay of the fireside chat visit here or the "Investors & Media/News & Events" section of the Company's website at https://gaintherapeutics.com.
Registered attendees can request one-on-one meetings with Gain management via their Oppenheimer banking representative.
If you are unable to attend the conference and would like to schedule a meeting with Gain management, please contact ir@gaintherapeutics.com.
About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson's disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan(TM) platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking StatementsThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. Forward-looking statements include all statements other than statements of historical fact contained in this release, including statements regarding the development of our current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; our anticipated cash runway; industry environment and potential licensing opportunities; and the potential therapeutic and clinical benefits of our product candidates. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our other filings with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.
Investors:Gain Therapeutics, Inc. Apaar Jammu Director, Investor Relations and Public Relationsajammu@gaintherapeutics.com
LifeSci Advisors LLCChuck PadalaManaging Directorchuck@lifesciadvisors.com
Media:Russo Partners LLC Nic Johnson and Elio Ambrosionic.johnson@russopartnersllc.comelio.ambrosio@russopartnersllc.com(760) 846-9256
COMTEX_473824943/2010/2026-02-19T07:00:06
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25th through Thursday, February 26th.
Fireside Chat Details
Date: Wednesday, February 25, 2026
Time: 1:20 p.m. ET
To access a replay of the fireside chat visit here or the "Investors & Media/News & Events" section of the Company's website at https://gaintherapeutics.com.
Registered attendees can request one-on-one meetings with Gain management via their Oppenheimer banking representative.
If you are unable to attend the conference and would like to schedule a meeting with Gain management, please contact ir@gaintherapeutics.com.
About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson's disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan(TM) platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking StatementsThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. Forward-looking statements include all statements other than statements of historical fact contained in this release, including statements regarding the development of our current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; our anticipated cash runway; industry environment and potential licensing opportunities; and the potential therapeutic and clinical benefits of our product candidates. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our other filings with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.
Investors:Gain Therapeutics, Inc. Apaar Jammu Director, Investor Relations and Public Relationsajammu@gaintherapeutics.com
LifeSci Advisors LLCChuck PadalaManaging Directorchuck@lifesciadvisors.com
Media:Russo Partners LLC Nic Johnson and Elio Ambrosionic.johnson@russopartnersllc.comelio.ambrosio@russopartnersllc.com(760) 846-9256
COMTEX_473824943/2010/2026-02-19T07:00:06
25.57% $0.67
